

DAFTAR PUSTAKA

- AJCC Cancer Staging Manual 7th Edition, 2010, VII, pp.345-76
- Andorfer, C., Necela, B.M., Thompson, E.A., Perez, E., 2011. MicroRNA signature: Clinical biomarker for the diagnosis and treatment of breast cancer. *Trends in Molecular Medicine*. 17(6), pp. 313-319.
- Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F. et al., 2011. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. USA*. 108(12), pp.5003–8.
- Aryandono, T., Harijadi., Soeripto., 2006. Survival from Operable Breast Cancer: Prognostic Factor in Yogyakarta Indonesia. *Asian Pasifik J.Cancer*. vol.7:455-9
- Asaga, S., Kuo, C., Nguyen, T., Terpenning, M., Giuliano, A.E., Hoon, D.D.B., 2011. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. *Clin. Chem*. 57(1), pp.84–91.
- Castaneda, C.A., Cortes-Funes, H., Gomez, H.L., Ciruelos, E.M., 2010. The phosphatidyl inositol 3-kinase / AKT signaling pathway in breast cancer. *Springer. Sci*. pp.751–759.
- Chan, J.A., Krichevsky, A.M. & Kosik, K.S., 2005. MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells. *Cancer Res*. pp.6029–6033.
- Cheang, M., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J. et al., 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *Journal of the National Cancer Institute*. 101(10), pp. 736-750.
- Checka, C.M., Chun, J.E., Schnabel, F.R., Lee, J., Toth, H., 2012. The relationship of mammographic density and age: implications for breast cancer screening. *Am. J. Roentgenol*. 198(3), pp.W292–5.
- Chen, X., Ba, Y., Ma, L., Chai, X., Yin, Y., Wang, K. et al., 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res*. 18(10), pp.997–1006.
- Chen, X., Zhang, J., Zen, K., Zhang, C.Y., 2011. MicroRNAs as Blood-based Biomarkers of Cancer., *MicroRNAs in Cancer Translation Research*., W. C. S. Cho, ed., Dordrecht: *Springer. Sci*. pp. 499-532.

- Cortez, M.A & Calin, G.A., 2009. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. *Expert opinion on biological therapy*, 9(6), pp. 703-711.
- Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., et al., 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. *Proc. Natl. Acad. Sci. USA*. 102(10), pp.3627-32.
- Fairell, R.E., 2005. RNA Methodologies: A Laboratory Guide for Isolation and Characterization. New York: Elsevier Academic Press.
- Faivre, S., Kroemer, G & Raymond, E., 2006. Current development of mTOR inhibitor as anticancer agents. *Nature reviews. Drug discovery*. 5(8), pp. 671-688.
- Fraga, D., Meulia, T., Fenster, S., 2008. Real Time PCR. In: Current protocol essential laboratory techniques. New York (US): John Wiley, Inc, pp. 10.3.1-10.3.33.
- Garzon, R., Marcucci, G., Croce, C.M., 2010. Targeting MicroRNAs in Cancer: Rationale, Strategies and Challenges. *Nat. Rev. Drug. Discov*. 9(10), pp.775-789.
- Gibbs, RA, 1990. DNA amplification by the polymerase chain reaction. *Anal Chem*. 62, pp. 1202-1214.
- Giglio, s., Monis, PT., Saint, CP., 2003. Demonstration of preferential binding of SYBR Green I to specific DNA fragments in real-time multiplex PCR. *Nucleic Acid Res*. 31, pp.e136.
- Heneghan, H.M., Miller, N. & Kerin, M.J., 2010. MiRNAs as biomarkers and therapeutic targets in cancer. *Curr. Opin. Pharmacol*. 10(5), pp.543-50.
- Hernandez-Aya, L.F. & Gonzalez-Angulo, A.M., 2011. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. *Oncologist*. 16(4), pp.404-14.
- Huang, Y., Yang, Y., Zhang, X.H., Yu, X.L., Wang, Z.B., Cheng, X.C., 2013. MicroRNA-21 gene and cancer. *Med. Oncol*. 30(1), p.376.
- Huang, G.L., Zhang, X.H., Guo, G.L., Huang, K.T., Yang, K.Y., Shen, X. et al., 2009. Clinical significance of miR-21 expression in breast cancer: of invasive ductal carcinoma. *Oncol. Rep*.(2), pp.673-679.
- Hugget, J., 2005. Real Time RT-PCR normalization: Strategies and Consideration. *Genes and Immunity*, p.1-6

- Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytsky, Y., Tryndyak, V.P., Chekhun, V.F. et al., 2008. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol. Cancer Ther.* 7(7), pp.2152–9.
- Kunej, T., Godnic, I., Horvat, S., Zorc, M., Calin, G.A., 2013. Cross Talk Between MicroRNA and Coding Cancer Genes. *Cancer J.* 18(3), pp.223–231.
- Lawrie, C.H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P., Pulford, K. et al., 2008. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br. J. Haematol.* 141(5), pp.672–5.
- Li, J., Huang, H., Sun, L., Yang, M., Pan, C., Chen, W. et al., 2009. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. *Clin. Cancer Res.* 15(12), pp.3998–4008.
- Li, J., Jia, S., Zhang, W., Zhang, Y., Fei, X., Tian, R., 2013. Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patient with Positive Hormone Receptor and Positive HER2 in China Who Cannot Afford the Target Therapy. *ISRN Oncology*. Vol. 2013: 8
- Li, L.Q., Li, L.X., Wang, L., Du, W.J., Guo, R., Liang, H.H., et al., 2012. Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. *Cell. Physiol. Biochem.* 30(3), pp.631–41.
- Lowery, A.J., Miller, N., Devaney, A., McNeill, R.E., Davoren, P.A., Lemetre, C., et al., 2009. MicroRNA signature predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. *Breast Cancer Research: BCR*, 11(3), pp.1-18.
- Meng, F. Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, Tushar., 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology*. 133(2), pp.647–58.
- Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogossova-Agadjanyan, E.L. et al., 2008. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc. Natl. Acad. Sci. USA*. 105(30), pp.10513–8.
- Mo, M.H., Chen, L., Fu, Y., Wang, W., Fu, S.W., 2012. Cell-free Circulating miRNA Biomarkers in Cancer. *J. Cancer*. 3, pp.432–48.

- Molinari, F. & Frattini, M., 2013. Functions and Regulation of the PTEN Gene in Colorectal Cancer. *Front. Oncol.* 3(January), p.326.
- Negrini, M. & Calin, G.A., 2008. Breast cancer metastasis: a microRNA story. *Breast Cancer Res: BCR.* 10(2), p.203.
- O'Day, E. & Lal, A., 2010. MicroRNAs and their target gene networks in breast cancer. *Breast Cancer Res: BCR.* 12(2), p.201.
- Pan, X., Wang, Z.-X. & Wang, R., 2010. MicroRNA-21: A novel therapeutic target in human cancer. *Cancer Biol Ther.* 10(12), pp.1224–1232.
- Payne, SJL., Bowen, RL., Jones, JL. & Wells, CA, 2008. Predictive markers in breast cancer-the present Histopathology, 52, pp. 82-90.
- Prat, A & Baselga, J., 2008. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. *Nature clinical practice. Oncology.*, 5(9), pp. 531-542.
- Qian, B., Katsaros, D., Lu, L., Preti, M., Durando, A., Arisio, R. et al., 2009. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. *Breast Cancer Res Treat.*, 117(1), pp.131–40.
- Qi, L., Bart, L., Tan, L. P., Platteel, I., Sluis, T. V. D., Huitema, S. et al., 2009. Expression of miR-21 and its target (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. *BMC cancer.*, 9, p.163.
- Radojicic, J., Zaravinos, A., Vrekoussis, T., Kafousi, M., Spandidos, D., Stathopoulos, E. N., 2011. MicroRNA expression analysis in triple negative (ER, PR, Her2/neu) breast cancer. *Cell Cycle.*, 10(3), pp. 507-517.
- Ren, J., Zhu, D., Liu, M., Sun, Y., Tian, L. et al., 2010. Downregulation of miR-21 modulates Ras expression to promote apoptosis and suppress invasion of Laryngeal squamous cell carcinoma. *Eur. J. Cancer (Oxford, England: 1990)*, 46(18), pp.3409–16.
- Riskesdas, 2013. Riset Kesehatan Dasar. Available from: URL: http://www.litbang.go.id/sites/download/rkd2013/Laporan_Riskesdas2013.
- Saal, L.H., Holm. K., Maurer. M., Memeo. L., Su. T. Wang, X. et al., 2005. PIK3CA mutations correlate with hormone receptor, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Research.*, 65(7), pp. 2554-2559.

- Salmena, L., Carracedo, A. & Pandolfi, P.P., 2008. Tenets of PTEN tumor suppression. *Cell*, 133(3), pp.403–14.
- Sastroasmoro, S. & Ismael, S., 2011. Dasar-dasar Metodologi Penelitian Klinis. Ed ke-4. Sagung Seto, Jakarta.
- Sayed, D. & Abdellatif, M., 2010. AKT-ing via microRNA. *Cardiovasc. Res.* pp.3213–3217.
- Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K., 2014. Clinical relevance of circulating cell-free microRNA in cancer. *Nature reviews. Clinical oncology*. 11(3), pp. 145-56.
- Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Müller, V., Pantel, K. et al., 2012. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. *Breast Cancer Res. Treat.* 134(3), pp.933–41.
- Selcuklu, S.D., Donoghue, M.T. A & Spillane, C., 2009. miR-21 as a key regulator of oncogenic processes. *Biochem. Soc. Trans.* 37(Pt 4), pp.918–25.
- Shenouda, S.K. & Alahari, S.K., 2009. MicroRNA function in cancer : oncogene or a tumor suppressor ? *Springer Sci.* pp.369–378.
- Singh, R. & Mo, Y., 2013. Role of microRNAs in breast cancer. *Cancer Biol. Ther.* pp.201–212.
- Song, M.S., Salmena, L. & Pandolfi, P.P., 2012. The functions and regulation of the PTEN tumour suppressor. *Mol. Cell. Biol.* 13(5), pp.283–96.
- Tran, B & Bedard, P.L., 2011. Luminal B breast cancer and novel therapeutic targets. *Breast cancer research: BCR*. 13(6), p. 221.
- Turchinovich, A., Weiz, L., Langheinz, A., Burwinkel, B. et al., 2011. Characterization of extracellular circulating microRNA. *Nucleic Acid Res.* 39(16), pp.7223–7233.
- Vandesompele, J., De Paepe, A., Speleman, F., 2002. Elimination of primer-dimer artifact and genomic coamplification using a two-step SYBR green I real time RT-PCR. *Anal Biochem.* 303, pp.95-98.
- Villarreal-garza, C., Cortes, J., Andre, F., Verma, S., 2012. mTOR inhibitor in the management of hormone receptor-positive breast cancer: The latest evidence and future direction. *Annals of Oncology*. 23(10), pp. 2526-2535.

- Volinia, S., Calin, G.A., Liu, G.C., Ambs, S., Cimmino, A., Petrocca, F. et al., 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc. Natl. Acad. Sci. USA*. 103(7), pp.2257–61.
- Wang, Z., Lu, B., Wang, H., Cheng, Z., Yin, Y., MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. *Archives of medical research*. 42(4), pp.281-90.
- Xiong, B., Cheng, Y., Ma, L., Zhang, C. et al., 2013. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. *Int. J. Oncol*. 42(1), pp.219–28.
- Xu, L.F., Wu, Z.P., Chen, Y., Zhu, Q.S., Hamidi, S., Navab, R., 2014. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. *J. Pone*. 9(8), p.e103698.
- Yager, JD., Davidson, NE, 2006. Mechanisms of disease, estrogen carcinogenesis in breast cancer. *New england Journal of medicine*, 354, pp.270-82.
- Yan, L.X., Huang, X.F., Shao, Q., Huang, M.Y., Deng, L., Wu, Q.L. et al., 2008. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA (New York, N.Y.)*, 14(11), pp.2348–60.
- Yu, D.C., Li, Q.G., Ding, X.W., Ding, Y.T., 2011. Circulating MicroRNAs: Potential Biomarkers for Cancer. *Int. J. Mol. Sci*. 12(3), pp.2055–63.
- Zhang, B.G., Li, J.F., Yu, B.Q., Zhu, Z.G., Liu, B.Y., Yan, M., 2012. MicroRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. *Oncol. Rep*. 27(4), pp.1019–26.
- Zhang, M.H., Man, H.T., Zhao, X.D., Dong, N., Ma, S.L., 2014. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). *Biomed. Rep*. 2(1), pp.41–52.
- Zhang, Z.J. & Ma, S.L., 2012. MiRNAs in breast cancer tumorigenesis (Review). *Oncol. Rep*. pp.903–910.
- Zhu, W., Qin, W., Atasoy, U., Sauter, E.R., 2009. Circulating microRNAs in breast cancer and healthy subjects. *BMC. Res.2*, p.89.